Lilly drug fizzles in breast cancer study, casting doubt on potential blockbuster
This article was originally published in Scrip
Executive Summary
Eli Lilly’s drug ramucirumab failed in a study of breast cancer patients, diminishing hopes that the experimental therapy may prove to be an effective and big-selling treatment for an array of diseases.